Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -8103.88% is 12% above its 5-year average of -9184.73%, near the high end of its 5-year range (-30802.44%–-3129.22%).
37.38% above its 12-month average of -12942.18%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -9077.88%.
EBITDA MARGIN
-8103.88%
EBITDA MARGIN AVG TTM
-12942.18%
EBITDA MARGIN AVG 3Y
-8417.92%
EBITDA MARGIN AVG 5Y
-9184.73%
EBITDA MARGIN AVG 10Y
-7642.83%
EBITDA MARGIN AVG 15Y
-6777.39%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+37.38%
CURRENT VS 3Y AVG
+3.73%
CURRENT VS 5Y AVG
+11.77%
CURRENT VS 10Y AVG
-6.03%
CURRENT VS 15Y AVG
-19.57%
CURRENT VS 20Y AVG
N/A
Cardiff Oncology, Inc.
Market Cap
$82.47M
EBITDA Margin
-8103.88%
TTM Avg
-12942.18%
3Y Avg
-8417.92%
5Y Avg
-9184.73%
Market Cap
$83.82M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.18M
EBITDA Margin
-3237.56%
TTM Avg
-3237.56%
3Y Avg
-2112.78%
5Y Avg
-1492.65%
Market Cap
$81.79M
EBITDA Margin
-63075.78%
TTM Avg
-211942.49%
3Y Avg
-892870.62%
5Y Avg
-626625.43%
Market Cap
$84.13M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$81.38M
EBITDA Margin
-398.90%
TTM Avg
-349.10%
3Y Avg
-274.94%
5Y Avg
-268.47%
Market Cap
$80.88M
EBITDA Margin
-4911.29%
TTM Avg
-4911.29%
3Y Avg
-4895.51%
5Y Avg
-4835.22%
Market Cap
$85.24M
EBITDA Margin
31.45%
TTM Avg
-14.67%
3Y Avg
-906.21%
5Y Avg
-1050.55%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | $82.47M | -8103.88% | -12942.18% | -8417.92% | -9184.73% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $83.82M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $83.18M | -3237.56% | -3237.56% | -2112.78% | -1492.65% |
| LENSAR Inc (LNSR)vs › | $82.47M | -34.36% | -23.48% | -28.76% | -37.09% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $81.79M | -63075.78% | -211942.49% | -892870.62% | -626625.43% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.38M | -398.90% | -349.10% | -274.94% | -268.47% |
| Humacyte, Inc. (HUMA)vs › | $80.88M | -4911.29% | -4911.29% | -4895.51% | -4835.22% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.24M | 31.45% | -14.67% | -906.21% | -1050.55% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
Gross Margin
100.0%
EBITDA Margin
-8103.9%
Operating Margin
-8256.3%
Net Margin
-7884.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -9077.88% |
| 2026-03-31 | -30802.44% |
| 2025-12-31 | -3129.22% |
| 2025-09-30 | -9566.67% |
| 2025-06-30 | -12134.71% |
| 2025-03-31 | -12985.32% |
| 2024-12-31 | -8262.25% |
| 2024-09-30 | -7575.76% |
| 2024-06-30 | -7631.90% |
| 2024-03-31 | -5283.41% |
| 2023-12-31 | -6557.05% |
| 2023-09-30 | -7597.87% |
| 2023-06-30 | -11212.96% |
| 2023-03-31 | -14412.05% |
| 2022-12-31 | -7270.31% |
| 2022-09-30 | -9582.80% |
| 2022-06-30 | -11434.07% |
| 2022-03-31 | -14922.97% |
| 2021-12-31 | -7077.44% |
| 2021-09-30 | -8009.30% |
| 2021-06-30 | -9970.59% |
| 2021-03-31 | -7393.06% |
| 2020-12-31 | -5349.60% |
| 2020-09-30 | -3123.53% |
| 2020-06-30 | -9272.09% |
| 2020-03-31 | -5889.71% |
| 2019-12-31 | -4240.02% |
| 2019-09-30 | -7900.64% |
| 2019-06-30 | -2969.44% |
| 2019-03-31 | -2367.42% |
| 2018-12-31 | -5059.34% |
| 2018-09-30 | -4116.10% |
| 2018-06-30 | -3763.95% |
| 2018-03-31 | -4396.56% |
| 2017-12-31 | -1888.33% |
| 2017-09-30 | -4448.74% |
| 2017-06-30 | -5463.39% |
| 2017-03-31 | -10306.06% |
| 2016-12-31 | -13832.26% |
| 2016-09-30 | -10908.17% |
| 2016-06-30 | -9330.13% |
| 2016-03-31 | -8550.23% |
| 2015-12-31 | -9185.94% |
| 2015-09-30 | -11010.40% |
| 2015-06-30 | -13095.08% |
| 2015-03-31 | -3764.06% |
| 2014-12-31 | -7926.40% |
| 2014-09-30 | -6786.71% |
| 2014-06-30 | -5723.42% |
| 2014-03-31 | -2889.61% |
| 2013-12-31 | -5919.63% |
| 2013-09-30 | -6938.60% |
| 2013-06-30 | -4791.75% |
| 2013-03-31 | -1991.27% |
| 2012-12-31 | -872.69% |
| 2012-09-30 | -485.40% |
| 2012-06-30 | -2982.49% |
| 2012-03-31 | -3291.15% |
| 2011-12-31 | -2591.53% |
| 2011-09-30 | -1326.51% |
| 2011-06-30 | -807.47% |
| 2011-03-31 | -805.35% |
| 2010-12-31 | -390.48% |
| 2010-09-30 | -10766.67% |
| 2010-06-30 | -1750.00% |
